Again, this illustrates the potential of WGS and multi-gene panels to identify co-occurring cancer gene mutations (e.g. RAD51C and FH) that pose genetic risks (breast/ovarian cancer) beyond the patient's primary diagnosis (leiomyoma). This evidence concerns the gene FH and ovarian carcinoma.